Catalysts for $ABBV
477 tracked
Jan 23, 2025
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Jan 23, 2025
approval
DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Jan 23, 2025
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Dec 20, 2024
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Dec 20, 2024
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Dec 20, 2024
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Nov 22, 2024
approval
VRAYLAR (CARIPRAZINE HYDROCHLORIDE) — FDA approval
CARIPRAZINE HYDROCHLORIDE
→
Oct 16, 2024
approval
VYALEV (FOSCARBIDOPA) — FDA approval
(foscarbidopa + foslevodopa)
→
Jul 30, 2024
approval
ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE) — FDA approval
ORIAHNN (COPACKAGED)
→
Jun 18, 2024
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jun 18, 2024
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
May 9, 2024
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
May 9, 2024
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
May 9, 2024
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Apr 26, 2024
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 26, 2024
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Apr 26, 2024
approval
RINVOQ LQ (UPADACITINIB) — FDA approval
upadacitinib
→
Mar 18, 2024
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Mar 18, 2024
approval
DEPAKOTE ER (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Mar 18, 2024
approval
DEPAKOTE (DIVALPROEX SODIUM) — FDA approval
divalproex sodium DR
→
Mar 8, 2024
approval
ESCITALOPRAM OXALATE — FDA approval
AbbVie Inc.
→
Mar 4, 2024
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Mar 4, 2024
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Feb 22, 2024
approval
IMBRUVICA (IBRUTINIB) — FDA approval
AbbVie Inc.
→
Jan 3, 2024
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Jan 3, 2024
approval
SKYRIZI (RISANKIZUMAB-RZAA) — FDA approval
risankizumab
→
Nov 14, 2023
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Nov 3, 2023
approval
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jun 22, 2023
approval
RINVOQ (UPADACITINIB) — FDA approval
upadacitinib tartrate ER
→
Jun 12, 2023
approval
LINZESS (LINACLOTIDE) — FDA approval
linaclotide
→